| Literature DB >> 35741573 |
Fernando Cruz-Mendoza1, Fernando Jauregui-Huerta1, Adriana Aguilar-Delgadillo1, Joaquín García-Estrada1, Sonia Luquin1.
Abstract
The c-fos gene was first described as a proto-oncogene responsible for the induction of bone tumors. A few decades ago, activation of the protein product c-fos was reported in the brain after seizures and other noxious stimuli. Since then, multiple studies have used c-fos as a brain activity marker. Although it has been attributed to neurons, growing evidence demonstrates that c-fos expression in the brain may also include glial cells. In this review, we collect data showing that glial cells also express this proto-oncogene. We present evidence demonstrating that at least astrocytes, oligodendrocytes, and microglia express this immediate early gene (IEG). Unlike neurons, whose expression changes used to be associated with depolarization, glial cells seem to express the c-fos proto-oncogene under the influence of proliferation, differentiation, growth, inflammation, repair, damage, plasticity, and other conditions. The collected evidence provides a complementary view of c-fos as an activity marker and urges the introduction of the glial cell perspective into brain activity studies. This glial cell view may provide additional information related to the brain microenvironment that is difficult to obtain from the isolated neuron paradigm. Thus, it is highly recommended that detection techniques are improved in order to better differentiate the phenotypes expressing c-fos in the brain and to elucidate the specific roles of c-fos expression in glial cells.Entities:
Keywords: astrocytes; c-fos; glial cell; microglia; neurons; oligodendrocytes
Year: 2022 PMID: 35741573 PMCID: PMC9221432 DOI: 10.3390/brainsci12060687
Source DB: PubMed Journal: Brain Sci ISSN: 2076-3425
Figure 1The Fos gene family members. The picture shows a comparative structure of the products of the fos gene, all of which contain a basic leucine zipper domain, but only c-fos and FosB have a c-terminal transactivator domain (c-TAD). It also indicates the high homology level in the basic leucine zipper domain, which is more variable in other regions.
Figure 2Cell signaling pathways that might induce c-fos expression.
Figure 3Illustration of the main astrocyte subtypes.
Figure 4Activation states in microglial cells. Schematic representation of an M0 (left), M1 (center), and M2 (right) microglia.
Papers evidencing c-fos expression in astrocytes. Arrows indicate ↑ increased expression or ↓ diminished expression under different stimulation models.
| Paper | Effect | Model | Approach | Methodology | Studied Area | Species |
|---|---|---|---|---|---|---|
| [ | ↑ After 1 h | Heat shock insult | In vivo | Immunohistochemical | Thalamus, hippocampus, corpus callosum, internal capsule, and fornix/fimbria | Rat |
| [ | ↑ After 30 min | Mitogens and growth factor exposure | In vitro | Northern blot | Primary cultures of cortical astrocytes | Rat |
| [ | ↑ After 30–60 min | Muscarinic and adrenergic agonist exposure | In vitro | Northern blot | Primary cultures of cortical astrocytes | Rat |
| [ | -↑ After 30 min mRNA and 2 h protein | -Mitogen exposure | In vitro | Northern blot and immunohistochemical | Primary cultures of neocortical astrocytes | Rat |
| [ | ↑After 30 min | Damage-associated molecular pattern (DAMPs) | In vitro | Northern blot | Primary cultures of cortical astrocytes | Rat |
| [ | ↑After 30 min | Endothelin exposure | In vitro | Northern blot | Rat astrocytoma C6 cells (C6-S and C6-V subclones) and primary cultures of cortical and striatal astrocytes | Rat/Mouse |
| [ | ↑After 30–60 min | Scratch wound of culture astrocytes | In vitro | Quantitative reverse transcriptase polymerase chain reaction (RT-PCR | Primary cultures of cortical astrocytes | Rat |
| [ | ↑0.5–2 h, peak at 1 h | Ischemic model (mineral oil) | In vitro | RT-PCR | Primary cultures of cortical astrocytes | Rat |
| [ | ↑After 30 min | Proinflammatory factor exposure | In vitro | Northern blot and flow cytometry | Primary cultures of cortical astrocytes | Mouse |
| [ | ↑After 15–60 min | Chemical hypoxia (0.5 mM cyanide for 1 h) | In vitro | Northern blot | RBA-2 type 2 astrocytes cell line | Rat |
| [ | ↑ NA | Heat shock insult | In vitro | Western blot | Primary cultures of astrocytes | Mouse |
| [ | ↑1 h, peak at 2 h | LPS administration | In vivo | Immunohistochemical | Hypothalamic supraoptic nucleus, posterior and anterior pituitary | Rat |
| [ | ↑0.5–1 h, peak at 30 min | Adenovirus (Ad.βGal) exposure | In vitro | Northern blot | Primary cultures of cortical astrocytes | Mouse |
| [ | ↑1 h | Proinflammatory factor exposure | In vitro | Northern blot | Primary cultures of astrocytes | Rat |
| [ | ↑After 15–30 min, peak at 30 min | Glutamate stimulation in excitotoxic levels | In vitro | Northern blot and immunohistochemical | Primary cortical glial cell cultures | Rat |
| [ | ↑After 1 h | Bradykinin exposure | In vitro | Western blot and RT-PCR | RBA-1 cell line | Rat |
| [ | c-fos binding to mCFH promoter | NA | In vitro | Electrophoretic mobility shift assay (EMSA) and supershift assay | Astrocyte 2.1 (Ast 2.1) cell line and primary astrocytes, | Mouse |
| [ | Nuclear translocation | Amitriptyline exposure | In vitro | Western blot and real-time PCR | Primary cultures of astrocytes | Rat |
| [ | ↑After 1 h | Forskolin and IL-1 exposure | In vitro/ in vivo | Western blot and qPCR | Human cortical astrocytes/KO mouse | Human/ Mouse |
| [ | ↓ After 1 h at low doses (0.5–1 μM) | Fluoxetine exposure | In vitro | Western blot and RT-PCR | Primary cultures of astrocytes | Mouse |
| [ | ↑ After 90 min | Viral vector injection and CNO administration | In vivo | Immunohistochemical | Hippocampus | Mouse |
| [ | ↑ NA | Experimental autoimmune encephalomyelitis (EAE) | In vivo | Immunolabeling-enabled three-dimensional imaging of solvent-cleared organs (iDISCO) and flow cytometry | TetTag-cFos reporter mice | Mouse |
Papers evidencing c-fos expression in oligodendrocytes.
| Paper | Effect | Model | Approach | Methodology | Studied Area | Species |
|---|---|---|---|---|---|---|
| [ | ↑After 30 min | Mitogenic and growth factors exposure | In vitro | Northern blot and immunohistochemical | OPCs isolated from mixed glial cell cultures | Rat |
| [ | ↑After 0.25–8 h, peak at 1 h | Basic fibroblast growth factor (bFGF) exposure | In vitro | Northern blot and immunohistochemical | OPCs isolated from mixed glial cell cultures | Rat |
| [ | ↑After 0.25–6 h, peak at 1 h | Glutamate exposure | In vitro | Northern blot | OPCs isolated from mixed glial cell cultures | Rat |
| [ | ↑After 30–60 min | Carbachol exposure | In vitro | Northern blot and immunohistochemical | OPCs isolated from mixed glial cell cultures | Rat |
| [ | ↑After 30–60 min | NE exposure | In vitro | Western and Northern blot | OPCs isolated from mixed glial cell cultures | Rat |
| [ | ↑ 1, 6, and 9 days after induction with progressive increases | Experimental anterior optic nerve ischemia | In vivo | Quantitative real-time PCR (qRT-PCR) and immunohistochemical | Optic nerve | Mouse |
| [ | ↑After 90 min | d-LSD exposure | In vivo | Immunohistochemical | Prefrontal cortex | Rat |
| [ | Delayed downregulation | Ethanol administration | In vitro | Western blot | CG-4 glial cell line | Rat |
| [ | ↑After 2 hours/day of SMF stimulation (0.3 T) for a period of 14 days | Static magnetic field (SMF) stimulation | In vitro | qRT-PCR | Human OPCs derived from induced pluripotent stem cells | Human |
Papers evidencing c-fos expression in microglia.
| Paper | Effect | Model | Approach | Methodology | Studied Area | Species |
|---|---|---|---|---|---|---|
| [ | ↑After 30 min (mRNA) | 10-50-fold higher doses of glutamate than physiological exposure | In vitro | RT-PCR, Western blot, and immunohistochemical | Primary cortical microglial cells | Rat |
| [ | ↑p-c-fos after 2 h (KA) | Kainic acid (KA) exposure | In vitro | Western blot | BV-2 microglia cell line | Mouse |
| [ | ↓ Dose-dependent (Dex) | LPS/ATP and Dexmedetomi-dine (Dex) treatment | In vitro | PCR, Western blot, and immunohistochemical | Human microglia clone 3 cell line | Human |
| [ | ↑2 h after treatment (BV-2 cells) | LPS treatment | In vivo/in vitro | PCR, Western blot, and immunohistochemical | BV-2 microglia cell line/hippocampus and hypothalamus | Mouse/rat |
| [ | ↑6, 12, and 24 h of treatment | Paraquat and LPS exposure | In vitro | qRT-PCR | BV-2 microglia cell line | Mouse |